Rheumnow Podcast
Dr. Cush
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Episodes
Mentioned books
May 8, 2025 • 59min
Lupus Unlocked - Journal Club
In this first webinar of RheumNow's Lupus Unlocked campaign, Journal Club discussed two articles:
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Furie R, et al. NEJM. 2025 Feb 7. doi: 10.1056
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1) Rovin BH. Lancet. 2021 May 29;397(10289)
Speakers:
Brad Rovin, MD
Richard Furie, MD
Jack Cush, MD
May 2, 2025 • 22min
Keys to Mastery (5.2.2025)
Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This months campaign on Lupus is sponsored by Aurinia.
May 1, 2025 • 15min
A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis Sponsored by AbbVie Medical Affairs + Health Impact
Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.
Apr 26, 2025 • 28min
Rheumatology Believe It or Not (4.25.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?
Apr 18, 2025 • 23min
Osteoarthritis Risky Business (4.18.2025)
Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow.com. Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients.
Apr 11, 2025 • 18min
EMR Messaging Woes (4.11.2025)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
Apr 4, 2025 • 22min
An Epidural Letdown (4.4.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
**Correction: a Tweet from 3/18 podcast, had incorrect information. Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to PLACEBO (not deucravacitinib as reported) in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 16 (NOT 15) in 684 moderate-to-severe plaque PsO pts https://buff.ly/dMbTbML
Apr 1, 2025 • 11min
Biomarkers in RA
Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.
Mar 28, 2025 • 23min
Cancer Survival with TNF Inhibitors (3.28.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Mar 21, 2025 • 33min
ERA, APPs, & Alpha GAL (3.21.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Listen in for 2 new case questions - Ask Cush Anything.
